LncRNAs could play a vital role in osteosarcoma treatment: Inhibiting osteosarcoma progression and improving chemotherapy resistance

Shi Xiaotong; Li Xiao; Liao Shiyu; Bi Zhiguo; Feng Chunyang; Liu Jianguo

doi:10.3389/fgene.2022.1022155

LncRNAs could play a vital role in osteosarcoma treatment: Inhibiting osteosarcoma progression and improving chemotherapy resistance

Front Genet. 2023 Jan 16:13:1022155. doi: 10.3389/fgene.2022.1022155. eCollection 2022.

Authors

Shi Xiaotong¹, Li Xiao¹, Liao Shiyu¹, Bi Zhiguo¹, Feng Chunyang², Liu Jianguo¹

Affiliations

¹ Department of Orthopedics, The First Hospital of Jilin University, Changchun, China.
² Department of Obstetrics and Gynecology, Renji Hospital of Shanghai Jiao Tong University, Shanghai, China.

Abstract

Osteosarcoma (OS) is one of the most common primary solid malignant tumors in orthopedics, and its main clinical treatments are surgery and chemotherapy. However, a wide surgical resection range, functional reconstruction of postoperative limbs, and chemotherapy resistance remain as challenges for patients and orthopedists. To address these problems, the discovery of new effective conservative treatments is important. Long non-coding RNAs (lncRNAs) are RNAs longer than 200 nucleotides in length that do not encode proteins. Researchers have recently found that long non-coding RNAs are closely associated with the development of OS, indicating their potentially vital role in new treatment methods for OS. This review presents new findings regarding the association of lncRNAs with OS and summarizes potential clinical applications of OS with lncRNAs, including the downregulation of oncogenic lncRNAs, upregulation of tumor suppressive lncRNAs, and lncRNAs-based treatment to improve chemotherapy resistance. We hope these potential methods will be translated into clinical applications and greatly reduce patient suffering.

Keywords: chemotherapy resistance; long non-coding RNA (LncRNA); osteosarcoma-pathology; progression; regulatory mechanism.

Publication types

Review

Grants and funding

This work was supported by the Jilin Provincial Development and Reform Commission (2020C030-2), the Health Department of Jilin Province (JLSCZD 2019-02), and the Science and Technology Department of Jilin Province (20200404181YY).